Joseph Kumka
Board Pearls
Board Pearls is a gastroenterology board review built around clinical reasoning, not recall. Each episode takes one high-yield topic and works it the way you would on rounds: a case to anchor it, the framework that sorts the differential, and the specific decisions the exam rewards. The gastroenterology series covers the full blueprint across nine modules: esophagus, stomach and duodenum, small bowel, colon, pelvic floor, liver, pancreas and biliary, endoscopy, and the cross-cutting topics. Episodes are grouped by chapter and built from the primary guidelines and pivotal trials the boards draw...
Be sure to visit the podcast's website and support the creator: www.boardpearls.com
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Episodes
Chapter 36, Ep 5 of 5: Hereditary Pancreatic Cancer and Coordination 16.07.2026 16:42
Episode five closes the chapter with hereditary pancreatic cancer and the family-systems coordination that binds every syndrome together. The gating principle is absolute lifetime risk, not relative risk: surveillance begins above roughly five percent, so STK11, CDKN2A, PRSS1, and familial kindreds qualify on genotype alone while BRCA1, BRCA2, ATM, PALB2, and Lynch enter only with a family-history...
Chapter 36, Ep 4 of 5: Hamartomatous Polyposis and Diffuse Gastric Cancer 16.07.2026 17:43
Episode four moves from adenoma to hamartoma, where the dominant risk shifts away from colorectal cancer. STK11 drives Peutz-Jeghers, and the resection threshold is calibrated to intussusception rather than cancer, so any small bowel polyp over one centimeter comes out. PTEN drives Cowden, where the cancer burden tracks baseline PI3K signaling into breast and thyroid and the GI role is recognition...
Chapter 36, Ep 3 of 5: Adenomatous Polyposis: FAP and MUTYH 16.07.2026 9:24
Episode three works the adenomatous polyposis syndromes by their governing logic: if you know the gene, you know the polyp count, the polyp type, and the surgery. APC drives classic FAP toward near-certain colorectal cancer by forty, the same gene at its ends produces the softer attenuated phenotype, and biallelic MUTYH mimics attenuated FAP through an autosomal recessive pattern of affected sibli...
Chapter 36, Ep 2 of 5: Lynch Syndrome and Gene-Specific Risk 16.07.2026 13:35
Episode two takes Lynch syndrome, the syndrome the diagnostic framework most often surfaces, and anchors everything to one idea: lifetime cancer risk varies sharply by gene, and that gene-specific risk sets each surveillance interval to the dwell time of preinvasive disease in that organ. MLH1 and MSH2 carriers drive high colorectal and endometrial risk, while MSH6 flips uterine cancer above color...
Chapter 36, Ep 1 of 5: Tumor Screening and Reflex Testing 16.07.2026 9:06
Episode one of the Hereditary GI Cancer Syndromes chapter builds the diagnostic framework the rest of the series depends on. The organizing idea: universal tumor testing catches the carriers that pedigree gatekeeping misses, because family history alone overlooks thirty to fifty percent of them. The four-protein immunohistochemistry pattern then decides the next move, with combined MLH1 and PMS2 l...
Chapter 35, Ep 6 of 6: Post-Bariatric Pregnancy and Biliary Disease 16.07.2026 12:14
Episode six closes the chapter on two luminal problems governed by anatomy and timing. Post-bariatric pregnancy reads every rule off what the surgery changed: bypassed duodenum drops iron and calcium, reduced parietal cell exposure drops B12, the bypassed pylorus invalidates the OGTT, and mesenteric defects plus a gravid uterus produce internal hernia, so right upper quadrant pain after gastric by...
Chapter 35, Ep 5 of 6: Inflammatory Bowel Disease in Pregnancy 16.07.2026 9:54
Episode five flips a deeply intuitive instinct: pregnancy is not the time to back off immunosuppression, because the measured danger to the fetus is active maternal disease, not active maternal medicine. Once that principle is in place the medication rules become predictable, anything that maintained remission is continued and a small set of mechanism-toxic drugs is held. The molecular centerpiece...
Chapter 35, Ep 4 of 6: Incidental and Pre-Existing Liver Disease 16.07.2026 18:14
Episode four takes the hepatic disease that is not caused by pregnancy but is reshaped by it. Viral hepatitis turns on virus-specific decisions: the tenofovir-plus-HBIG-and-vaccine stack that decisively cuts HBV vertical transmission, universal HCV screening with treatment deferred, genotype-driven HEV severity, and the empiric acyclovir that any pregnant patient with high transaminases and low bi...
Chapter 35, Ep 3 of 6: Pregnancy-Specific Liver Diseases 16.07.2026 19:17
Episode three covers the liver diseases that exist only because pregnancy is occurring, the syndromes for which delivery is the definitive treatment. It opens on intrahepatic cholestasis, where a stillbirth-risk curve inflecting at bile acids of one hundred drives delivery timing and a normal GGT separates it from obstruction. It then works through the preeclampsia, HELLP, and AFLP spectrum, teach...
Chapter 35, Ep 2 of 6: GERD and Peptic Ulcer Disease 16.07.2026 7:51
Episode two takes the upper-GI symptom that rides on the same pregnancy physiology as hyperemesis. GERD dominates because progesterone loosens the lower esophageal sphincter while estrogen strengthens the gastric mucosal barrier, so ulcers stay uncommon. The management is a stepwise sequence built on local-then-systemic safety logic, and the reasoning is that the rules fall out of mechanism rather...
Chapter 35, Ep 1 of 6: Pregnancy Physiology and Hyperemesis 16.07.2026 14:55
Episode one of the GI in Pregnancy chapter sets the physiologic baseline that every later stem depends on. The organizing idea is that pregnancy shifts a predictable set of labs, so any deviation pregnancy does not itself cause is by definition pathologic. From there it walks the volume, CBC, and liver-test changes, the fetal-protective imaging menu, and the antiemetic sequence for nausea and hype...
Chapter 34, Ep 4 of 4: Immune Checkpoint Inhibitor Toxicity 16.07.2026 21:06
Episode four closes the module on checkpoint inhibitor toxicity, one entity with many organ targets, where releasing the brakes on T cells means the same cells recognize self. Drug class predicts the toxicity rate, with anti-CTLA-4 broad and severe, anti-PD-1 focal and milder, and combination highest, while grade drives therapy through a universal seventy-two-hour escalation window. The colitis al...
Chapter 34, Ep 3 of 4: HIV GI Disease and Typhlitis 16.07.2026 18:36
Episode three covers the non-transplant immunocompromised GI host, where two settings that look unrelated share one logic: identify the host state, and the host state opens a tiered differential. In HIV that state is the CD4 count, which converts a long pathogen list into strata that drive workup and surfaces the pre-antiretroviral-era entities still seen in late presenters, AIDS cholangiopathy, g...
Chapter 34, Ep 2 of 4: Hematopoietic Cell Transplant Gut GVHD 16.07.2026 11:57
Episode two takes the other host state hiding behind the word transplant: the hematopoietic cell transplant recipient whose donor immune system attacks the host. The post-transplant timeline organizes everything, with the first twenty-one days belonging to conditioning toxicity rather than graft-versus-host disease, so the timeline decides which diagnosis is even allowed. Gut disease is staged by...
Chapter 34, Ep 1 of 4: Solid Organ Transplant GI Disease 16.07.2026 17:05
Episode one of the GI in the Immunocompromised Host chapter starts with a single recognition move: a transplant recipient on calcineurin inhibitor plus mycophenolate plus prednisone with diarrhea could be any of five entities at once, and time since transplant is the variable that reorders the differential. The first month belongs to the surgeon, the one-to-twelve-month window belongs to opportuni...
Chapter 33, Ep 5 of 5: Immunocompromised-Host Enteric Infections 16.07.2026 17:41
The immunocompromised gut expands the pathogen list, and the organizing move is that each organism lives behind a specific cue that names the therapy: name the host, the stain, and the histology, and you name the drug. CMV gives the owl-eye inclusion at the ulcer base treated with ganciclovir, with foscarnet as salvage when UL97 mutations break the prodrug pathway. MAC gives the PAS-positive, acid...
Chapter 33, Ep 4 of 5: Parasitic and Viral Diarrheas 16.07.2026 11:36
The parasitic diarrheas sort by exposure history, so the workup follows the suspected pathogen rather than a generic ova-and-parasite exam. Giardia comes from untreated water with a single-dose tinidazole answer, Entamoeba histolytica from endemic travel with two-stage tissue-then-luminal therapy, and Strongyloides is the pre-steroid serology question that prevents seventy-percent-mortality hyperi...
Chapter 33, Ep 3 of 5: Travelers' Diarrhea and Bacterial Toxins 16.07.2026 12:44
The community-acquired diarrheas separate cleanly once you group by acquisition pattern rather than symptoms, because the exposure history predicts the pathogen and the pathogen predicts the treatment. Travelers' diarrhea selects the empiric antibiotic by region and resistance, while rifaximin stays in the noninvasive niche because it is non-absorbed. Shiga-toxin-producing E. coli flips the rule e...
Chapter 33, Ep 2 of 5: C. diff Recurrence Toolkit 16.07.2026 8:54
Recurrence is the dominant management problem in C. diff, and this episode organizes the entire toolkit around a single mechanism: the spore. Surviving spores germinate once the antibiotic stops, so every tool either keeps colonic drug above the killing threshold across successive germination waves or restores the commensal community that denies spores a niche. The drug you reach for depends on wh...
Chapter 33, Ep 1 of 5: C. diff Diagnosis and First-Episode Treatment 16.07.2026 15:26
Episode one of the GI Infections chapter builds C. diff around two competing problems: the defaults moved off metronidazole and vancomycin, and asymptomatic colonization is common enough that the wrong test drives unnecessary treatment. The organizing idea is that diagnosis exists to separate active disease from colonization, while treatment exists to get the right drug to the colonic lumen at the...
Chapter 32, Ep 4 of 4: Minerals and Trace Elements 16.07.2026 10:29
Episode four closes the chapter with the minerals and trace elements, which run on the same logic as the vitamins: each element has a specific biochemical role and a specific exposure or pathology context that produces its phenotype. The boards favor the pairs that turn on a single mechanism, zinc inducing metallothionein to trap copper, cholestasis blocking biliary manganese excretion, and Brazil...
Chapter 32, Ep 3 of 4: Fat-Soluble and Water-Soluble Vitamins 16.07.2026 20:55
Episode three reads the vitamins the way the boards test them, where every micronutrient produces a stereotyped phenotype that is the recognition cue on a stem. Behind each cue is a biochemical mechanism, and the same mechanism predicts the at-risk population and the replacement strategy. Memorizing the symptom list is the wrong frame; learning the mechanism lets the phenotype, the population, and...
Chapter 32, Ep 2 of 4: Parenteral Nutrition and Short Bowel Syndrome 16.07.2026 17:30
Episode two takes the patient whose gut cannot do the work. Parenteral nutrition is a tool for a non-functional gut, with composition rules that follow from chemistry rather than biology and indication discipline that follows from trial data. Its long-term complications are driven by the loss of enteral stimulation, from gallbladder stasis and IFALD to manganese parkinsonism and catheter biofilm i...
Chapter 32, Ep 1 of 4: Refeeding, Malnutrition, and Enteral Access 16.07.2026 15:42
Episode one of the GI Nutrition chapter builds the inpatient nutrition framework and the enteral access decisions. The organizing idea is that the labs lie and the instinct to feed faster is usually wrong. Refeeding syndrome is what happens when a starvation-adapted patient meets a carbohydrate load, so the active intervention is restraint with thiamine before glucose. Hospital malnutrition is not...
Chapter 31, Ep 4 of 4: Esophageal Perforation and Ogilvie Syndrome 16.07.2026 13:39
Episode four closes the chapter with two emergencies that run on the same cue-plus-threshold-plus-intervention shape, where the threshold is a mechanism in disguise. For esophageal perforation the clock starts when the wall tears, and the twenty-four hour window separates clean primary closure from sealed stent and drainage because the mediastinal tissue planes change from friend to enemy. For acu...
Similar podcasts
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.